Blase Polite to Neuroendocrine Tumors
This is a "connection" page, showing publications Blase Polite has written about Neuroendocrine Tumors.
Connection Strength
0.501
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
Score: 0.188
-
Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases. Am J Surg. 2024 03; 229:17-23.
Score: 0.175
-
Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery. 2021 01; 169(1):162-167.
Score: 0.138